Keyur Mehta

13.7k total citations · 1 hit paper
32 papers, 4.3k citations indexed

About

Keyur Mehta is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Keyur Mehta has authored 32 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 23 papers in Cancer Research and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Keyur Mehta's work include Breast Cancer Treatment Studies (22 papers), HER2/EGFR in Cancer Research (16 papers) and Cancer Treatment and Pharmacology (12 papers). Keyur Mehta is often cited by papers focused on Breast Cancer Treatment Studies (22 papers), HER2/EGFR in Cancer Research (16 papers) and Cancer Treatment and Pharmacology (12 papers). Keyur Mehta collaborates with scholars based in Germany, Switzerland and United States. Keyur Mehta's co-authors include Sibylle Loibl, Gϋnter von Minckwitz, Bernd Gerber, Jens Huober, Michael Untch, Carsten Denkert, Jens‐Uwe Blohmer, Holger Eidtmann, Peter A. Fasching and Christian Jackisch and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Keyur Mehta

32 papers receiving 4.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

2012 1.8k citations Gϋnter von Minckwitz, Michael Untch et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Keyur Mehta	3.0k	2.9k	1.1k	821	624	32	4.3k
Valentina Nekljudova	3.9k 1.3×	4.0k 1.3×	1.7k 1.6×	1.0k 1.2×	1.1k 1.7×	159	6.1k
Hervé Bonnefoi	2.5k 0.9×	2.8k 0.9×	758 0.7×	408 0.5×	994 1.6×	135	5.0k
Annette Lebeau	2.5k 0.8×	2.2k 0.8×	1.2k 1.1×	957 1.2×	456 0.7×	99	4.4k
A Brown	3.1k 1.0×	2.3k 0.8×	1.6k 1.4×	741 0.9×	342 0.5×	19	4.2k
William M. Sikov	1.7k 0.6×	2.3k 0.8×	553 0.5×	412 0.5×	660 1.1×	93	3.4k
Lee K. Tan	2.6k 0.9×	1.8k 0.6×	2.2k 2.0×	912 1.1×	495 0.8×	59	5.1k
Mauro G. Mastropasqua	2.9k 1.0×	2.5k 0.8×	1.3k 1.2×	430 0.5×	898 1.4×	96	4.6k
Tibor Tot	1.5k 0.5×	2.1k 0.7×	1.4k 1.2×	672 0.8×	871 1.4×	103	4.0k
Malcolm Hayes	1.2k 0.4×	1.4k 0.5×	943 0.9×	332 0.4×	626 1.0×	92	3.2k
Laslo Roman	1.4k 0.5×	4.4k 1.5×	524 0.5×	1.4k 1.7×	1.3k 2.1×	31	5.2k

Countries citing papers authored by Keyur Mehta

Since Specialization

Citations

This map shows the geographic impact of Keyur Mehta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keyur Mehta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keyur Mehta more than expected).

Fields of papers citing papers by Keyur Mehta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keyur Mehta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keyur Mehta. The network helps show where Keyur Mehta may publish in the future.

Co-authorship network of co-authors of Keyur Mehta

This figure shows the co-authorship network connecting the top 25 collaborators of Keyur Mehta. A scholar is included among the top collaborators of Keyur Mehta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keyur Mehta. Keyur Mehta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Huober, Jens, Marion van Mackelenbergh, Andreas Schneeweiß, et al.. (2023). Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy. npj Breast Cancer. 9(1). 23–23. 20 indexed citations

Furlanetto, Jenny, Gϋnter von Minckwitz, Bianca Lederer, et al.. (2019). Fatal events during clinical trials: an evaluation of deaths during breast cancer studies. Breast Cancer. 26(6). 826–834. 1 indexed citations

Loibl, Sibylle, Silvia Darb‐Esfahani, Jens Huober, et al.. (2016). Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. Clinical Cancer Research. 22(11). 2675–2683. 34 indexed citations

Denkert, Carsten, Karsten E. Weber, Kristin Krappmann, et al.. (2016). Risk assessment after neoadjuvant chemotherapy in luminal breast cancer: A prospectively planned validation of gene expression based and clinical prognostic scores in 428 residual tumor samples from two neoadjuvant clinical trials.. Journal of Clinical Oncology. 34(15_suppl). 522–522. 1 indexed citations

Loibl, Sibylle, Christian Jackisch, Bianca Lederer, et al.. (2015). Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Breast Cancer Research and Treatment. 152(2). 377–387. 77 indexed citations

Klauschen, Frederick, Stephan Wienert, Wolfgang Schmitt, et al.. (2014). Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study. Clinical Cancer Research. 21(16). 3651–3657. 78 indexed citations

Darb‐Esfahani, Silvia, Gϋnter von Minckwitz, Carsten Denkert, et al.. (2014). Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes. BMC Cancer. 14(1). 546–546. 67 indexed citations

Lück, Hans‐Joachim, Kristina Lübbe, Mattea Reinisch, et al.. (2014). Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer. Breast Cancer Research and Treatment. 149(1). 141–149. 19 indexed citations

Loibl, Sibylle, Bettina Conrad, Nadia Harbeck, et al.. (2014). Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA*. Breast Care. 9(3). 169–174. 10 indexed citations

10.

Denkert, Carsten, Gϋnter von Minckwitz, Jan C. Brase, et al.. (2014). Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: Prediction of response to carboplatin-based chemotherapy.. Journal of Clinical Oncology. 32(15_suppl). 510–510. 7 indexed citations

11.

Minckwitz, Gϋnter von, Jens‐Uwe Blohmer, Serban Dan Costa, et al.. (2013). Response-Guided Neoadjuvant Chemotherapy for Breast Cancer. Journal of Clinical Oncology. 31(29). 3623–3630. 265 indexed citations

12.

Denkert, Carsten, Jens Huober, Sibylle Loibl, et al.. (2013). HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Research. 15(1). R11–R11. 49 indexed citations

13.

Minckwitz, Gϋnter von, Sibylle Loibl, Jens‐Uwe Blohmer, et al.. (2013). Abstract 4699: Responsecharacteristics and overall survival of 781 patients with triple-negativebreast cancer - a meta-analysis on 7 German neoadjuvant studies.. Cancer Research. 73(8_Supplement). 4699–4699. 4 indexed citations

14.

Wenners, Antonia, Keyur Mehta, Sibylle Loibl, et al.. (2012). Neutrophil Gelatinase-Associated Lipocalin (NGAL) Predicts Response to Neoadjuvant Chemotherapy and Clinical Outcome in Primary Human Breast Cancer. PLoS ONE. 7(10). e45826–e45826. 44 indexed citations

15.

Untch, Michael, Peter A. Fasching, Gottfried E. Konecny, et al.. (2011). Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups. Journal of Clinical Oncology. 29(25). 3351–3357. 370 indexed citations

16.

Guo, Xinrong, Sibylle Loibl, Michael Untch, et al.. (2011). Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy. Breast Care. 6(4). 279–283. 11 indexed citations

17.

Loibl, Sibylle, Berit Müller, Gϋnter von Minckwitz, et al.. (2011). Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment. 130(2). 477–487. 166 indexed citations

18.

Huober, Jens, Carsten Denkert, Hans Tesch, et al.. (2010). Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Research and Treatment. 124(1). 133–140. 220 indexed citations

19.

Minckwitz, Gϋnter von, Mahdi Rezai, Sibylle Loibl, et al.. (2010). Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study. Journal of Clinical Oncology. 28(12). 2015–2023. 155 indexed citations

20.

Loibl, Sibylle, Manfred Kaufmann, Keyur Mehta, et al.. (2006). Darbepoetin Alfa as Primary Prophylaxis of Anemia in Patients with Breast Cancer Treated Preoperatively with Docetaxel/Doxorubicin/Cyclophosphamide. PubMed. 3(2). 103–109. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact